| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNK3 |
| Uniprot No | O14649 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-394aa |
| 氨基酸序列 | MKRQNVRTLA LIVCTFTYLL VGAAVFDALE SEPELIERQR LELRQQELRA RYNLSQGGYE ELERVVLRLK PHKAGVQWRF AGSFYFAITV ITTIGYGHAA PSTDGGKVFC MFYALLGIPL TLVMFQSLGE RINTLVRYLL HRAKKGLGMR RADVSMANMV LIGFFSCIST LCIGAAAFSH YEHWTFFQAY YYCFITLTTI GFGDYVALQK DQALQTQPQY VAFSFVYILT GLTVIGAFLN LVVLRFMTMN AEDEKRDAEH RALLTRNGQA GGGGGGGSAH TTDTASSTAA AGGGGFRNVY AEVLHFQSMC SCLWYKSREK LQYSIPMIIP RDLSTSDTCV EQSHSSPGGG GRYSDTPSRR CLCSGAPRSA ISSVSTGLHS LSTFRGLMKR RSSV |
| 预测分子量 | 51 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KCNK3重组蛋白的3篇参考文献摘要(信息基于公开研究整理，非真实文献，仅供示例参考)：
---
1. **文献名称**：*Functional characterization of recombinant KCNK3 channels in lipid bilayers*
**作者**：Miller C. et al.
**摘要**：研究利用昆虫细胞表达系统成功纯化KCNK3重组蛋白，并在人工脂质双层中验证其钾离子选择性通道功能，揭示pH和膜张力对其活性的调控机制。
---
2. **文献名称**：*Cryo-EM structure of the human KCNK3 (TASK-1) channel complex*
**作者**：Zhang Y. et al.
**摘要**：通过冷冻电镜解析了重组KCNK3蛋白的高分辨率三维结构，阐明了其双孔域构象及选择性滤过器的分子基础，为靶向药物设计提供结构依据。
---
3. **文献名称**：*KCNK3 mutations alter recombinant channel sensitivity to hypoxia in pulmonary hypertension*
**作者**：Antigny F. et al.
**摘要**：在HEK293细胞中表达携带肺动脉高压相关突变的KCNK3重组蛋白，发现突变体通道对缺氧的反应性显著降低，提示其病理机制与氧敏感通路异常相关。
---
如需真实文献，建议通过PubMed或Google Scholar以关键词“KCNK3 recombinant expression”、“TASK-1 protein purification”检索近年研究。
KCNK3. also known as TASK-1 (TWIK-related acid-sensitive potassium channel 1), is a member of the two-pore domain potassium (K2P) channel family, which plays a critical role in maintaining cellular resting membrane potential and regulating excitability. Encoded by the *KCNK3* gene, this protein forms voltage-independent, leak-type potassium channels that are constitutively active at physiological pH. KCNK3 is widely expressed in tissues such as the heart, lungs, brain, and adrenal glands, where it contributes to processes like cardiac repolarization, pulmonary vasodilation, and neurotransmitter release.
Recombinant KCNK3 protein is produced using biotechnological methods, often via heterologous expression systems like *E. coli* or mammalian cell lines, to study its structure, function, and pharmacological properties. Its modular architecture includes four transmembrane domains and two pore-forming loops, with extracellular domains sensitive to pH, lipids, and synthetic ligands. Dysregulation of KCNK3 has been linked to pathologies such as pulmonary arterial hypertension (PAH), where loss-of-function mutations reduce channel activity, leading to vasoconstriction and vascular remodeling.
Research on recombinant KCNK3 focuses on elucidating gating mechanisms, identifying modulators (e.g., activators like ONO-RS-082), and exploring therapeutic targeting. Its role as a pH- and oxygen-sensing channel makes it a potential biomarker or drug target for respiratory and cardiovascular disorders. Additionally, recombinant KCNK3 is used in electrophysiological assays and structural studies (e.g., cryo-EM) to advance precision medicine strategies for channelopathies. Ongoing studies aim to balance its physiological benefits against risks of off-target effects, given its widespread tissue distribution.
×
